Consumer Discretionary · Wholesale-Chemicals & Allied Products · NYSE · CIK 1674862 · FYE Sep 30 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $72.70Day −0.19%Mkt cap $3.3B1Y +41.3%Off 52W high −2.9%Vol (1Y) 41.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.4% of sh out |
| Days to cover9.7d |
| 13F net flow (QoQ)+0.42% |
| Top-10 13F concentration49.1% |
| Next report (est.)2026-10-27 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.84B |
| Earnings (TTM)$51.0M |
| ROE−35.4% |
| Net margin−46.3% |
| ROIC−17.5% |
| Debt / equity0.73× |
| Sales growth 3Y−8.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+25.7% |
| 1Y+41.3% |
| 3Y−14.5% |
| 5Y−5.7% |
| 10Y+52.2% |
| Since incept. (ann.)+5.9% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)41.1% |
| Ann. volatility (3Y)35.4% |
| Sharpe (1Y)1.19 |
| Sharpe (3Y)0.03 |
| Max drawdown (1Y)−24.2% |
| Max drawdown (3Y)−53.3% |
| Beta (3Y vs SPY)0.21 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 4.3M | $239M | 9.38% | +5.2% |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.8M | $157M | 6.15% | +4.8% |
| Standard Investments LLC | 2.6M | $146M | 5.73% | +0.0% |
| DIMENSIONAL FUND ADVISORS LP | 2.5M | $139M | 5.45% | +12.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.2M | $122M | 4.79% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $114M | 4.48% | new |
| AQR CAPITAL MANAGEMENT LLC | 2.0M | $110M | 4.39% | −11.3% |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.9M | $106M | 4.18% | +34.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 107.0% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 5,599,160 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-06-30 | 2026-07-28 | $0.35 | — | $497.0M | +7.3% |
| 2026-03-31 | 2026-04-28 | $0.34 | −47.7% | $482.0M | +0.6% |
| 2025-12-31 | 2026-02-02 | −$0.26 | — | $386.0M | −4.7% |
| 2025-09-30 | 2025-11-04 | — | — | $477.0M | −8.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-27 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Life Sciences 34% · Personal Care 31% · Specialty Additives 27% · Intermediates 7%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
